Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stake Lessened by Driehaus Capital Management LLC

Driehaus Capital Management LLC trimmed its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 615,836 shares of the company’s stock after selling 6,704 shares during the quarter. Driehaus Capital Management LLC’s holdings in Kiniksa Pharmaceuticals were worth $11,498,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Hhlr Advisors LTD. acquired a new position in Kiniksa Pharmaceuticals in the first quarter worth about $61,868,000. Vanguard Group Inc. lifted its holdings in Kiniksa Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 2,981,894 shares of the company’s stock worth $58,833,000 after buying an additional 16,595 shares during the last quarter. Rubric Capital Management LP grew its position in shares of Kiniksa Pharmaceuticals by 10.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after acquiring an additional 223,094 shares in the last quarter. Granahan Investment Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 35.2% in the 4th quarter. Granahan Investment Management LLC now owns 722,388 shares of the company’s stock valued at $12,671,000 after acquiring an additional 188,174 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Kiniksa Pharmaceuticals by 31.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock valued at $12,398,000 after acquiring an additional 157,741 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Stock Up 4.3 %

KNSA stock opened at $25.00 on Monday. The firm’s 50-day simple moving average is $25.49 and its 200 day simple moving average is $21.38. The stock has a market cap of $1.77 billion, a PE ratio of 227.27 and a beta of 0.33. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $14.12 and a fifty-two week high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. The business had revenue of $108.30 million during the quarter, compared to analyst estimates of $90.60 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The business’s revenue for the quarter was up 51.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.02) EPS. Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.29 EPS for the current fiscal year.

Insider Activity

In related news, CFO Mark Ragosa sold 24,248 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $24.79, for a total value of $601,107.92. Following the completion of the sale, the chief financial officer now owns 19,253 shares of the company’s stock, valued at $477,281.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Mark Ragosa sold 24,248 shares of the business’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $24.79, for a total transaction of $601,107.92. Following the sale, the chief financial officer now owns 19,253 shares of the company’s stock, valued at $477,281.87. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Eben Tessari sold 17,500 shares of the stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $24.99, for a total value of $437,325.00. Following the transaction, the chief operating officer now directly owns 116,975 shares of the company’s stock, valued at $2,923,205.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 278,064 shares of company stock valued at $7,165,254. Company insiders own 54.57% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on KNSA. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective for the company. Wedbush lifted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals has a consensus rating of “Buy” and an average target price of $33.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.